Table 4.

Treatment in newly diagnosed elderly/frail cHL

RegimenPhasenStageMedian age, yCRR, %PFSFrailReference
BV and anti PD-1 therapies in elderly/frail patients         
 BV 2 27 I-IV 78 73 Median, 10.5 mo 81% were impaired in ≥1 aspect of GA 84 
 BV (BREVITY) 2 38 II-IV 76 26 Median, 7.3 mo Median CIRS-G score was 6 in evaluable patients 85 
 BV (1.2 mg/m2) +bendamustine (HALO) 1/2 59 II-IV 70 63 54% at 2 y 79% 87 
 BV+DTIC 2 19 I-IV 69 68 Median PFS, 46.8 mo 50% 86,88 
 BV (1.8 mg/m2) +bendamustine (70 mg/m2) 2 20 I-IV 75 88 Median PFS, 40.3 mo 45% 86,88 
 BV+nivo (≤16 cycles) 2 21 II-IV 72 79 Median PFS not reached GA not reported* 88 
 BV+nivo (8 cycles) 2 46 II-IV 71 68 Median PFS, 21.8 mo GA not assessed† 89 
 Sequential BV→AVD‡ 2 48 II-IV 69 81 85% at 2 y Median CIRS-G score was 7 90 
Standard chemotherapies in elderly/frail patients         
 ABVD×6-8§ 3§ 23 II-IV 66 65 64% at 5 y — 83 
 Stanford V§ 3§ 21 II-IV 64 62 51% at 5 y — 83 
 ABVD×2+IFRT‖ 3‖ 70 I-II 64 96 70% at 5 y — 94 
 AVD×2+IFRT 3 82 I-II 66 98 70% at 5 y — 94 
 PVAG×6-8 2 59 II-IV 68 78 58% at 3y — 96 
RegimenPhasenStageMedian age, yCRR, %PFSFrailReference
BV and anti PD-1 therapies in elderly/frail patients         
 BV 2 27 I-IV 78 73 Median, 10.5 mo 81% were impaired in ≥1 aspect of GA 84 
 BV (BREVITY) 2 38 II-IV 76 26 Median, 7.3 mo Median CIRS-G score was 6 in evaluable patients 85 
 BV (1.2 mg/m2) +bendamustine (HALO) 1/2 59 II-IV 70 63 54% at 2 y 79% 87 
 BV+DTIC 2 19 I-IV 69 68 Median PFS, 46.8 mo 50% 86,88 
 BV (1.8 mg/m2) +bendamustine (70 mg/m2) 2 20 I-IV 75 88 Median PFS, 40.3 mo 45% 86,88 
 BV+nivo (≤16 cycles) 2 21 II-IV 72 79 Median PFS not reached GA not reported* 88 
 BV+nivo (8 cycles) 2 46 II-IV 71 68 Median PFS, 21.8 mo GA not assessed† 89 
 Sequential BV→AVD‡ 2 48 II-IV 69 81 85% at 2 y Median CIRS-G score was 7 90 
Standard chemotherapies in elderly/frail patients         
 ABVD×6-8§ 3§ 23 II-IV 66 65 64% at 5 y — 83 
 Stanford V§ 3§ 21 II-IV 64 62 51% at 5 y — 83 
 ABVD×2+IFRT‖ 3‖ 70 I-II 64 96 70% at 5 y — 94 
 AVD×2+IFRT 3 82 I-II 66 98 70% at 5 y — 94 
 PVAG×6-8 2 59 II-IV 68 78 58% at 3y — 96 

CIRS-G, Cumulative Illness Rating Scale-Geriatric comorbidity score; DTIC, dacarbazine; GA, geriatric assessment; IFRT, involved field radiation therapy.

*

Patients ≥60 year of age who were considered unfit for conventional chemotherapy were included in the study.

†

Patients were selected based on abnormal organ function that would render them poor candidates for standard chemotherapy.

‡

Patients received 2 cycles of BV followed by 6 cycles of AVD and then 4 cycles of BV consolidation in those who responded.

§

Secondary analysis of E2496 data.

‖

Secondary analysis of GHSG HD10 study data.

Secondary analysis of GHSG HD13 study data.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal